Iovance Biotherapeutics (IOVA) Misses Q2 EPS by 5c, reiterates guidance

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.33), $0.05 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $60 million versus the consensus estimate of $67.1 million.

GUIDANCE:

Iovance Biotherapeutics sees FY2025 revenue of $250-300 million, versus the consensus of $287.1 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Wolfe Research Starts Federal Realty Investment Trust (FRT) at Outperform
• Market Vectors Oil Services ETF (OIH) call put ratio 3.2 calls to 1 put as WTI Crude oil trades above $74
• Camden Property Trust (CPT) 4500 contracts of July 125 calls trade